throbber
AAPS PharmSciTech 2003; 4 (1) Article 1 (http://www.pharmscitech.org).
`Synergistic Effect of PEG-400 and Cyclodextrin to Enhance Solubility of
`Progesterone
`Submitted: November 20, 2002; Accepted: January 9, 2003
`Indranil Nandi1, Michelle Bateson2, Mohammad Bari3, and Hemant N. Joshi4
`1Geneva Pharmaceutical Technology Corp, 2400 Route 130 North, Dayton NJ 08810
`2Galen Limited, Millbrook, Larne BT40 2SH Northern Ireland
`3Forest Laboratories Inc, 330 Prospect Street, Inwood, NY 11096
`4Barr Laboratories, Pharmaceutical Research & Development, 2 Quaker Road, Pomona, NY 10970
`
`
`KEYWORDS: cosolvent, cyclodextrins, PEG-400, pro-
`gesterone, solubilization, synergism
`INTRODUCTION
`The addition of cosolvent to a formulation is a com-
`monly used method for improving the solubility of a
`drug. Polyethylene glycol (PEG)-400 is one of the most
`widely used cosolvents for improving the aqueous
`solubility of hydrophobic drugs. Cyclodextrins (CDs)
`also have been used to improve solubility and stability
`of drug compounds.1 Higher molecular weight PEGs
`have been used in conjunction with various CDs in
`solid dispersion systems.2 Harada3 reported that PEGs
`form complexes with α-CD and γ-CD, but not with β-
`CD. In the current study, therefore, β-CD was chosen to
`investigate the synergistic effects of CD and PEG-400
`on the solubility of a model hydrophobic drug.
`In CD aqueous solutions, the addition of propylene gly-
`col or ethanol has been reported to reduce the solubility
`of testosterone and ibuprofen.4 Hydroxypropyl methyl-
`cellulose (HPMC) was observed to increase the solubi-
`lization effect of CDs. The amount of CD needed in the
`solid dosage form was significantly lower in the pres-
`ence of HPMC.5 Enhancement of solubilization of
`ETH-615 and midazolam was reported in the presence
`of water-soluble polymers.6,7 Zung8 hypothesized that a
`series of alcohols have a synergistic effect on the cosol-
`vency and complexation of pyrene. Zung also sug-
`gested that the cosolvents could act as a space-
`regulating molecule to assist the drug to fit inside the
`CD cavity.
`
`Corresponding Author: Hemant N. Joshi, Barr Labo-
`ratories, Pharmaceutical Research & Development, 2
`Quaker Road, Pomona, NY 10970. Phone: (845) 362-
`7055; Fax: (845) 362-2774; Email:
`hjoshi@barrlabs.com.
`
`In this study, progesterone, a neutral hydrophobic com-
`pound, was selected as a model compound. The goal of
`the project was to test the hypothesis that PEG-400 and
`CD may have a synergistic effect on the solubility of
`progesterone. Captisol® (hepta sulfobutyl ether) and
`Trappsol® HPB (hydroxypropyl beta CD) were used as
`2 different types of CDs. Captisol possesses a negative
`charge, whereas Trappsol HPB is uncharged. The effect
`of polysorbate 80 on the synergism of PEG-CD in
`solubilization of the model compound also was exam-
`ined.
`
`MATERIALS AND METHODS
`Materials
`Progesterone, micronized powder, USP was purchased
`from Gerdina, CA. Captisol and Trappsol HPB were
`purchased from Cydex, Inc, Kansas City, KS, and
`CTD, Inc, High Spring, FL, respectively. PEG-400 and
`polysorbate 80 were obtained from Sigma and Spec-
`trum, respectively. All other chemicals used were of
`analytical grade and were used as is.
`Methods
`Solubility Experiments
`In the solubility experiments, progesterone was sus-
`pended in various solvents, namely: water, polysorbate
`80, PEG-400, and 3% and 6% aqueous solutions of
`Captisol and Trappsol HPB. The samples were shaken
`at 25°C ± 2°C for 24 hours and filtered through a 0.45-
`µm syringe filter. The drug concentration in the filtered
`solution was determined using high performance liquid
`chromatography (HPLC) after appropriate dilution with
`methanol. The cosolvent systems of PEG-400/water
`and PEG-400/water/polysorbate 80 were prepared by
`weight. The percentage of PEG-400 in the PEG-
`400/water cosolvent system was varied from 0.2% to
`90%. The solubilization capacity of cosolvent systems
`
` 1
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1040, Page 1
`
`

`

`AAPS PharmSciTech 2003; 4 (1) Article 1 (http://www.pharmscitech.org).
`
`Table 1. Solubility of Progesterone in Selected Vehicles at 25ºC ± 2°C
`
`Vehicles
`
`PEG-400
`
`Polysorbate 80
`
`3% Captisol® aqueous solution
`
`3% Trappsol® HPB aqueous solution
`
`6% Captisol®aqueous solution
`
`6% Trappsol® HPB aqueous solution
`
`Water
`
`Solubility of Progesterone (mg/mL)*
`
`15.3 ± 0.03
`
`11.9 ± 2.31
`
`1.6 ± 0.05
`
`1.1 ± 0.02
`
`5.0 ± 0.08
`
`1.3 ± 0.05
`
`0.007
`
`
`
`*Expressed as mean ± SD (n = 3)
`
`
`was investigated in a similar fashion as mentioned in
`this section. In another set of solubility experiments,
`the solubility of progesterone was determined in a 50%
`PEG-400/water system containing 3% Captisol or 3%
`Trappsol HPB in the presence of polysorbate 80.
`Chromatographic Analysis
`A simple chromatographic system was developed in-
`house to examine progesterone in the solubility sam-
`ples. The mobile phase consisted of acetonitrile and
`0.5% acetic acid solution (50:50, vol/vol). A 10-cm
`C18 column with a particle diameter of 5 µm was used.
`The flow rate was 1.2 mL/min and the wavelength of
`detection was 254 nm. The observed retention time for
`progesterone in this system was 5.9 minutes.
`RESULTS AND DISCUSSION
`Table 1 lists the solubility values of progesterone in
`selected vehicles. Progesterone has very poor water
`solubility (0.007 mg/mL) at 25°C ± 2°C. The solubility
`values of progesterone in PEG-400 and polysorbate 80
`were observed to be approximately 15.3 mg/mL and
`11.9 mg/mL, respectively. In solutions containing 3%
`Captisol or 3% Trappsol HPB, the solubility values
`were approximately 1.6 mg/mL and 1.1 mg/mL,
`respectively. The solubility increased in both systems
`with further addition of the CDs, although not to the
`same degree in each. It became obvious that PEG-400,
`polysorbate 80 and CDs help solubilization of proges-
`terone.
`The solubility of progesterone in PEG-400 decreased
`significantly with a small addition of water—from ap-
`proximately 15.3 mg/mL in 100% PEG-400 to 1.45
`
` 2
`
`mg/mL in 90% PEG-400 system. The solubility in a
`50% PEG-400/water system was found to be only 0.2
`mg/mL, showing a nonlinear decline. Table 2 lists the
`theoretical and observed solubility values of progester-
`one in the PEG-400/water systems containing 3%
`Trappsol HPB or 3% Captisol at 25°C ± 2°C. The data
`for the system containing 3% Trappsol HPB are de-
`picted in Figure 1. The theoretical solubility for PEG-
`400/water/3% CD systems were calculated by the addi-
`tion of solubilities in PEG-400/water systems and those
`observed in 3% CD solutions. In solutions containing
`Trappsol HPB, at lower PEG-400 concentrations (less
`than 50%), the observed solubility was significantly
`greater than the expected solubility. For example, the
`theoretical value in 5% PEG-400/water system contain-
`ing 3% Trappsol HPB was 1.11 mg/mL. The observed
`solubility of progesterone in the same system was 2.18
`mg/mL, indicating approximately a 96% increase com-
`pared to the theoretical value. In general, the improve-
`ment in solubility due to synergism was observed in
`samples containing 5% to 50% PEG-400 and 3%
`Trappsol HPB. In systems containing PEG-400 concen-
`trations greater than 60%, the synergistic effect de-
`creased, yielding observed solubilities close to the theo-
`retical values. Overall, PEG-400 and Trappsol HPB
`showed a synergistic effect in improving progesterone
`solubility in water. In the case of systems containing
`Captisol, no synergism was observed (Table 2) in im-
`proving the solubility of progesterone. The observed
`solubility was less than the theoretical solubility.
`Polysorbate 80 often is used in the PEG-400/water
`system as a surfactant. Different percentages of poly
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1040, Page 2
`
`

`

`AAPS PharmSciTech 2003; 4 (1) Article 1 (http://www.pharmscitech.org).
`Table 2. Solubility of Progesterone in PEG-400/Water Systems with 3% Trappsol ® HPB or 3% Captisol ® at
`25°C ± 2 °C
`
`Observed Value
`(with 3% Captisol®)
`
`% of PEG-400 in
`PEG-400/Wwater
`System
`
`Solubility of Progesterone (mg/mL)
`Observed Value
`Theoretical Value
`Theoretical Value
`with 3% Trappsol®
`(with 3% Captisol®)*
`(with 3% Trappsol®
`HPB (% increase+)
`HPB)*
`1.45
`3.05
`2.79 (9.4)
`2.55
`90
`1.06
`2.40
`2.09 (10.0)
`1.90
`70
`1.10
`1.80
`1.77 (36.1)
`1.30
`50
`1.11
`1.65
`1.91 (66.1)
`1.15
`30
`1.21
`1.61
`2.09 (88.3)
`1.11
`10
`ND
`1.61
`2.18 (96.4)
`1.11
`5
`1.18
`1.61
`1.61 (45.0)
`1.11
`1
`*The theoretical solubility is the solubility of progesterone in a PEG-400/water system without CD plus the solubility of
`progesterone in 3% CD aqueous solution.
`+% increase = (Observed solubility - theoretical solubility)*100/theoretical solubility
`Values in italics indicate that the observed values were greater than theoretical values.
`ND = not determined
`n=1 only few data points were listed in the table Figure 1 has all the points
`
`
`
`
`sorbate 80 (0%-12%) were added to a 50% PEG-
`400/water system containing 3% Trappsol HPB or 3%
`Captisol. The solubility of progesterone in a 50%
`PEG-400/water system without polysorbate 80 was
`observed to be 0.19 mg/mL. By adding polysorbate
`80, the solubility increased sequentially to 1.03
`mg/mL with 12% polysorbate 80. The observed solu-
`bility in a system containing Trappsol HPB were
`greater than the theoretical solubility for a system con-
`taining up to 6% polysorbate 80. The increase in solu-
`bility was 37% and 12% for samples containing 0%
`and 6% polysorbate 80 in the PEG-400/water system.
`Higher amounts of polysorbate 80 nullified the syner-
`gistic effect of PEG-400 and Trappsol HPB. In the
`case of Captisol, no synergistic effect was observed to
`improve the solubility.
`In early 1990s, it was believed that cosolvents reduced
`the solubilization capacity of CDs. The solubility of
`testosterone with hydroxypropyl-β-CD was reported to
`be lower in the presence of 80% ethanol.9 However, in
`recent years, polymers have been reported to improve
`the solubilization capacity of CDs. A synergism be-
`tween CDs and water-soluble polymers in solubilizing
`naproxen was observed.10 A mathematical model was
`developed to describe the combined effect of cosol-
`vency and complexation on fluasterone solubilization.11
`The most fundamental model for solubilization of a
`solute in a solvent involves liberation of a solute mole-
`
`cule, creation of a hole in the solvent, and accommoda-
`tion of the solute molecule in the solvent cavity.12 Work
`must be done to overcome the intermolecular forces of
`attraction in dissolving a solute. Four types of interac-
`tions, namely solute-solvent, ion-dipole, dipole-dipole,
`and hydrogen bonding-hydrophobic, have been re-
`ported. In addition, if the system involves a polymer,
`the conformation of polymer chains also plays a role in
`solute-solvent interactions.
`For a reaction (in this case, the solubilization of a solute
`in a solvent), free energy (∆F) is defined as ∆F = ∆H –
`T∆S, where terms H and S are enthalpy and entropy,
`respectively. For a spontaneous reaction to occur, the
`associated ∆F must decrease or ∆F has to be negative.
`The dissolution of a solute involves the breaking of
`solid-state bonds in the solute, which is normally an
`endothermic process. The incorporation of the liberated
`solute molecules in the solvent cage is normally an exo-
`thermic process. One has to consider such enthalpic and
`entropic contributions in understanding the mechanism
`of solubilization.
`Water as a solvent has some unique properties: a high
`level of hydrogen bonding, a sizable dielectric constant
`(80 at 20°C), and large surface tension (71 dynes/cm).
`The structure of PEG-400 is H-(O-CH2-CH2)n-OH,
`where n is approximately 8 to 9. This peculiar structure
`makes PEG miscible with water through hydrogen
`bonding. The hydrophobic hydrocarbon region helps to
`
` 3
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1040, Page 3
`
`

`

`AAPS PharmSciTech 2003; 4 (1) Article 1 (http://www.pharmscitech.org).
`
`Figure 1. Effect of 3% Trappsol ® HPB on the solubility of progesterone in PEG-
`400/water systems.
`
`
`
`
`break the hydrogen bonding between water molecules,
`thus reducing overall intermolecular interactions.13 In
`other words, PEG may assist to reduce the dipole mo-
`ment of water and allow hydrophobic compounds to fit
`in.
`The solubilization of solute molecules because of the
`inclusion complex in CD has been demonstrated in
`numerous cases. Although a variety of other factors,
`such as Van der Waals, hydrogen bonding, and hydro-
`phobic forces, play important roles in forming a stable
`complex, it mainly depends on the CD cavity and the
`accessibility of the drug molecule to the CD cavity. The
`type, length, and degree of substitution also affect the
`solubilization effect of CD. In the case of Captisol, the
`negative charge on the molecule also helps ion pairing
`with the cationic molecules.
`In the current study, the system examined is very com-
`plex with 4 components: progesterone, water, PEG-
`400, and CD. In the quaternary system in this study,
`the ∆F value must be more negative than the ∆F
`values of
`the PEG-400/water/progesterone or
`CD/water/progesterone systems. It is possible that ∆H
`might have a negative value and the entropic term
`
`must be positive (∆S > 0). The entropic term may in-
`dicate spontaneity or ease of preparation. Faucci and
`Mura10 studied synergism between CD and water-
`soluble polymers on naproxen solubility. They re-
`ported that water-soluble polymers increased the com-
`plexation efficacy of CDs toward naproxen. No previ-
`ous
`sonication or heating
`treatments of
`the
`drug/CD/polymer suspensions was necessary to obtain
`this favorable effect. The synergistic effect of CD and
`PEG-400 in the current study could be attributed to
`additional breaking of hydrogen bonds in water's
`structure and a decrease in the dipole moment. At
`PEG-400 concentrations of 50% and higher, the syn-
`ergistic effect diminished. It must be because of a shift
`from a predominantly aqueous environment to a PEG-
`based environment. In that case, water would be act-
`ing as a cosolvent instead of the main solvent. As a
`result, the polymer conformation and the effect of CD
`on the polymer conformation would affect the solubil-
`ity of the model drug.
`An evaluation may indicate that the negative charge on
`Captisol may have a role to play in this lack of syner-
`gism. The ionic charge of Captisol must have intro-
`duced some kind of orderliness in the solvent structure,
`
` 4
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1040, Page 4
`
`

`

`AAPS PharmSciTech 2003; 4 (1) Article 1 (http://www.pharmscitech.org).
`REFERENCES
`resulting in the lack of synergism. The addition of poly-
`sorbate 80 made the system more complex and ham-
`1. Loftsson T, Brewster ME. Pharmaceutical application of cyclo-
`pered the synergistic effects at higher concentrations.
`dextrin: drug solubilization and stabilization. J Pharm Sci.
`Polysorbate 80 is a strong surfactant, which reduces the
`1996;85:1017-1025.
`surface tension of water. The micelle formation of
`2. Wulff M, Alden M. Solid state studies of drug – cyclodextrin
`polysorbate 80 may be contributing to reduce the syn-
`inclusion complexes in PEG 6000 prepared by a new method. Eur
`J Pharm. 1999;8:269-281.
`ergistic effect. Such a micelle formation could be taking
`3. Harada A. Preparation and structures of supramolecules be-
`away water molecules, which are needed for the solubi-
`tween cyclodextrins and polymers. Coordin Chem Rev.
`lization. The exact role of polysorbate 80 in such a
`1996;148:115-133.
`complex system is unclear at this time.
`4. Loftsson T, Olafsdottir BJ, Fridriksdottir H, Jonsdottir S.
`
`Cyclodextrin complexations of NSAIDs: physicochemical charac-
`teristics. Eur J Pharm Sci. 1993;1:95-101.
`CONCLUSION
`5. Savolainen J, Jarvinen K, Taipale H, Jarho P, Loftsson T, Jar-
`vinen T. Co-administration of a water-soluble polymer increases
`PEG-400, polysorbate 80, and 2 CDs (Trappsol HPB
`the usefulness of cyclodextrins in solid dosage forms. Pharm Res.
`and Captisol) were used in an attempt to improve the
`1998;15:1696-1701.
`aqueous solubility of a model hydrophobic drug, pro-
`6. Loftsson T, Petersen DS. Cyclodextrin solubilization of ETH-
`gesterone. The aqueous solubility of progesterone im-
`615, a zwitterionic drug. Drug Dev Ind Pharm. 1998;24:365-370.
`proved significantly from 0.007 mg/mL by the addition
`7. Loftsson T, Gudmundsdottir H, Sigurjonsdottir JF, et al. Cyclo-
`of PEG-400, CDs, and polysorbate 80. In systems con-
`dextrin solubilization of benzodiazepines: formulation of mida-
`taining various amounts of PEG-400 and 3% Trappsol
`zolam nasal spray. Int J Pharm. 2001;212:29-40.
`HPB in water (% wt/wt), the theoretical solubility was
`8. Zung JB. Influence of alcohol addition on the γ-CD:pyrene
`complex. J Phys Chem. 1991;95:6701-6709.
`calculated by adding the solubilities in the individual
`systems. The observed solubility values were up to
`9. Pitha J, Hoshino T. Effect of ethanol on formation of inclusion
`complexes of hydroxypropylcyclodextrins with testosterone or
`96% higher than the theoretical values. The effect of
`with methyl orange. Int J Pharm. 1992;80:243-251.
`synergism was significant in 5% to 50% PEG-
`10. Faucci MT, Mura P. Effect of water-soluble polymers on
`400/water systems containing Trappsol HPB. Systems
`naproxen complexation with natural and chemically modified β-
`containing Captisol did not show such synergistic ef-
`cyclodextrins. Drug Dev Ind Pharm. 2001;27:909-917.
`fects. In general, the addition of polysorbate 80 to the
`11. Li P, Zhao L, Yalkowsky SH. Combined effect of cosolvent
`PEG-400/water systems containing CDs affected syn-
`and cyclodextrin on solubilization of nonpolar drugs. J Pharm Sci.
`ergism negatively.
`1999;88:1107-1111.
`12. Martin A. Physical Pharmacy: Physical Chemical Principles in
`
`the Pharmaceutical Sciences. Philadelphia, PA: Lea and Febiger;
`1993:223.
`13. Millard JW, Alvarex-Nunez FA, Yalkowsky SH. Solubiliza-
`tion by cosolvents—establishing useful constants for the log-linear
`model. Int J Pharm. 2002;245:153-166.
`
`
`
` 5
`
`
`IPR2018-01020 and IPR2018-01021, Exhibit 1040, Page 5
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket